会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 12. 发明申请
    • Breast cancer survival and recurrence
    • 乳腺癌存活和复发
    • US20050100933A1
    • 2005-05-12
    • US10871869
    • 2004-06-18
    • Mark ErlanderXiao-Jun MaWei WangJames Wittliff
    • Mark ErlanderXiao-Jun MaWei WangJames Wittliff
    • C12P19/34C12Q1/68G01N33/574
    • G01N33/57415C12Q1/6886C12Q2600/106C12Q2600/112C12Q2600/118C12Q2600/158
    • The invention provides for the identification and use of gene expression profiles, or patterns, with clinical relevance to breast cancer. In particular, the invention provides the identities of genes that are correlated with patient survival and breast cancer recurrence. The gene expression profiles may be embodied in nucleic acid expression, protein expression, or other expression formats and used to predict the survival of subjects afflicted with breast cancer and to predict breast cancer recurrence and. The profiles may also be used in the study and/or diagnosis of breast cancer cells and tissue, including the grading of invasive breast cancer, as well as for the study and/or determination of prognosis of a patient. When used for diagnosis or prognosis, the profiles may be used to determine the treatment of breast cancer based upon the likelihood of life expectancy and recurrence.
    • 本发明提供了与乳腺癌临床相关的基因表达谱或模式的鉴定和使用。 特别地,本发明提供了与患者存活和乳腺癌复发相关的基因的身份。 基因表达谱可以体现在核酸表达,蛋白质表达或其他表达形式中,并用于预测患有乳腺癌的受试者的存活并预测乳腺癌复发。 轮廓也可以用于乳腺癌细胞和组织的研究和/或诊断,包括浸润性乳腺癌的分级,以及用于研究和/或确定患者的预后。 当用于诊断或预后时,可根据预期寿命和复发的可能性来确定乳腺癌的治疗方法。
    • 13. 发明申请
    • Nucleic acid amplification
    • 核酸扩增
    • US20060246434A1
    • 2006-11-02
    • US10507932
    • 2003-03-14
    • Mark ErlanderRanelle SalungaTheresa TaylorLiang YouSteven Kunitake
    • Mark ErlanderRanelle SalungaTheresa TaylorLiang YouSteven Kunitake
    • C12Q1/68C12P19/34
    • C12P19/34C12N15/1096C12Q1/6846C12Q2525/179C12Q2525/143C12Q2521/107
    • A method of processing images includes the steps of retrieving a source image file including pixel date, creating a destination image file buffer, mapping the pixel data from the source image file to the destination image file buffer, and outputting pixel, data from the destination image file buffer as a destination image file. The step of mapping pixel data from the source image file to the destination image file buffer can include the step of interpolating the source image pixel data to produce pixel date for the destination image file buffer. Border pixel data can be added to the source image file to improve the efficiency interpolation step. The source image file can be a panoramic projection image file, and can include pixel data from a plurality of images. An apparatus for processing images in accordance with the method is also provided.
    • 处理图像的方法包括以下步骤:检索包括像素日期的源图像文件,创建目的地图像文件缓冲器,将源图像文件的像素数据映射到目的地图像文件缓冲器,以及从目的地图像输出像素数据 文件缓冲区作为目标映像文件。 将像素数据从源图像文件映射到目的地图像文件缓冲器的步骤可以包括内插源图像像素数据以产生目标图像文件缓冲器的像素日期的步骤。 可以将边缘像素数据添加到源图像文件中,以提高效率插值步骤。 源图像文件可以是全景投影图像文件,并且可以包括来自多个图像的像素数据。 还提供了一种根据该方法处理图像的装置。
    • 14. 发明申请
    • Diagnosis and treatment of breast cancer
    • 诊断和治疗乳腺癌
    • US20060154267A1
    • 2006-07-13
    • US11089097
    • 2005-03-24
    • Xiao-Jun MaMark ErlanderDennis SgroiEdward Enright
    • Xiao-Jun MaMark ErlanderDennis SgroiEdward Enright
    • G06Q10/00C12Q1/68G06Q50/00
    • C12Q1/6886C12Q2600/106C12Q2600/154C12Q2600/158G06Q50/22
    • Methods and compositions are provided for the identification of expression signatures in ER+ breast cancer cases, where the signatures correlate with responsiveness, or lack thereof, to treatment with tamoxifen or another antiestrogen agent against breast cancer The signature profiles are identified based upon sampling of reference breast tissue samples from independent cases of breast cancer and provide a reliable set of molecular criteria for predicting the efficacy of treating a subject with breast cancer with tamoxifen or another antiestrogen agent against breast cancer. Additional methods and compositions are provided for predicting responsiveness to tamoxifen or another antiestrogen agent against breast cancer in cases of breast cancer by use of multiple biomarkers. Two biomarkers display increased expression correlated with tamoxifen response while two other biomarkers display decreased expression correlated with tamoxifen response.
    • 提供了方法和组合物用于鉴定ER +乳腺癌病例中的表达标志,其中签名与反应性或缺乏相关,与他莫昔芬或另一种针对乳腺癌的抗雌激素剂的治疗相关。基于参考乳腺的抽样来鉴定签名谱 来自乳腺癌独立病例的组织样本,并提供可靠的一组分子标准,用于预测使用他莫昔芬或其他抗雌激素剂对乳腺癌进行乳腺癌治疗的受试者的疗效。 提供了另外的方法和组合物,用于通过使用多种生物标志物来预测在乳腺癌病例中对他莫昔芬或另一种抗雌激素剂对乳腺癌的反应性。 两种生物标志物显示与他莫昔芬反应相关的增加的表达,而另外两种生物标志物显示与他莫昔芬反应相关的降低的表达。
    • 15. 发明申请
    • Predicting breast cancer treatment outcome
    • 预测乳腺癌治疗结果
    • US20050239083A1
    • 2005-10-27
    • US10773761
    • 2004-02-06
    • Mark ErlanderXiao-Jun MaDennis Sgroi
    • Mark ErlanderXiao-Jun MaDennis Sgroi
    • C12M1/34C12Q1/68
    • C12Q1/6886C12Q2600/106C12Q2600/154C12Q2600/158
    • Methods and compositions are provided for the identification of expression signatures in ER+ breast cancer cases, where the signatures correlate with responsiveness, or lack thereof, to treatment with tamoxifen or another antiestrogen agent against breast cancer The signature profiles are identified based upon sampling of reference breast tissue samples from independent cases of breast cancer and provide a reliable set of molecular criteria for predicting the efficacy of treating a subject with breast cancer with tamoxifen or another antiestrogen agent against breast cancer. Additional methods and compositions are provided for predicting responsiveness to tamoxifen or another antiestrogen agent against breast cancer in cases of breast cancer by use of three biomarkers. Two biomarkers display increased expression correlated with tamoxifen response while the third biomarker displays decreased expression correlated with tamoxifen response.
    • 提供了方法和组合物用于鉴定ER +乳腺癌病例中的表达标志,其中签名与反应性或缺乏相关,与他莫昔芬或另一种针对乳腺癌的抗雌激素剂的治疗相关。基于参考乳腺的抽样来鉴定签名谱 来自乳腺癌独立病例的组织样本,并提供可靠的一组分子标准,用于预测使用他莫昔芬或其他抗雌激素剂对乳腺癌进行乳腺癌治疗的受试者的疗效。 提供了另外的方法和组合物,用于通过使用三种生物标志物来预测在乳腺癌病例中对他莫昔芬或另一种针对乳腺癌的抗雌激素剂的反应性。 两种生物标志物显示与他莫昔芬反应相关的增加的表达,而第三种生物标志物显示与他莫昔芬反应相关的降低的表达。